Agios Pharmaceuticals traded at $23.36 this Friday July 1st, increasing $1.19 or 5.37 percent since the previous trading session. Looking back, over the last four weeks, Agios Pharmaceuticals gained 20.54 percent. Over the last 12 months, its price fell by 58.08 percent. Looking ahead, we forecast Agios Pharmaceuticals to be priced at 22.73 by the end of this quarter and at 20.93 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
23.36
Daily Change
5.37%
Yearly
-58.08%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Astellas Pharma 2,095.50 37.00 1.80% 9.08%
Daiichi Sankyo 3,411.00 35.00 1.04% 45.40%
AbbVie 153.80 0.64 0.42% 33.54%
Agios Pharmaceuticals 23.36 1.19 5.37% -58.08%
Alnylam Pharmaceuticals 148.25 2.40 1.65% -13.52%
Amgen 245.55 2.25 0.92% -1.27%
Arrowhead Research 35.96 0.75 2.13% -43.04%
AstraZeneca 10,808.00 54.00 0.50% 24.54%
Bayer 57.24 -0.11 -0.19% 11.30%
Biogen 210.63 6.69 3.28% -39.60%
Bluebird Bio 4.28 0.14 3.38% -86.36%
BioMarin Pharmaceutical 84.98 2.11 2.55% -0.57%
Bristol-Myers Squibb 76.84 -0.16 -0.21% 14.77%
Epizyme 1.48 0.01 0.68% -81.41%
Exelixis 21.57 0.75 3.60% 18.13%
Gilead Sciences 62.36 0.55 0.89% -10.01%
GlaxoSmithKline 1,802.60 17.00 0.95% 25.84%
Immunogen 4.61 0.11 2.44% -28.30%
Incyte Corp 77.67 1.70 2.24% -7.07%
Ionis Pharmaceuticals 38.06 1.04 2.81% -4.66%
Jazz Pharmaceuticals 158.58 2.57 1.65% -12.63%
Eli Lilly 324.71 0.48 0.15% 38.79%
Merck & Co 92.42 1.25 1.37% 17.58%
Moderna Inc 149.95 7.10 4.97% -36.00%
Mirati Therapeutics 71.18 4.05 6.03% -57.53%
Nektar Therapeutics 3.75 -0.05 -1.32% -78.08%
Novartis 81.65 1.32 1.64% -3.02%
Novartis 84.36 -0.17 -0.20% -8.28%
Puma Biotechnology 2.78 -0.07 -2.46% -68.48%
Pfizer 52.31 -0.12 -0.23% 31.66%
Regeneron Pharmaceuticals 595.40 4.27 0.72% 2.01%
Roche Holding 322.10 1.70 0.53% -8.06%
Seattle Genetics 180.11 3.17 1.79% 14.52%
Sarepta Therapeutics 75.71 0.75 1.00% 0.62%
Vertex Pharmaceuticals 287.32 5.53 1.96% 43.27%

Indexes Price Day Year
USND 11128 99.11 0.90% -23.99%
US2000 1728 19.77 1.16% -25.07%

Agios Pharmaceuticals
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company's lead product candidate in its genetically defined disease (GDD) portfolio, mitapivat, is an activator for the treatment of hemolytic anemias. The Company’s clinical candidate, mitapivat, is in Phase III studies which is developed for the treatment of pyruvate kinase (PK), deficiency, thalassemia, and sickle cell disease (SCD). The Company is also developing AG-946, a clinical-stage, next-generation oral activator of pyruvate kinase R (PKR) enzymes, which is in Phase I clinical study. The mitapivat is an orally available small molecule and a potent activator of the PKR enzymes.